Phase II Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
Summary
The purpose of this phase II study is to evaluate the safety and efficacy of entinostat plus nivolumab in patients with unresectable or metastatic cholangiocarcinoma and pancreatic adenocarcinoma.
General Information
NCT#: NCT03250273
Study ID: J1798
Trial Phase: Phase II
Trial Sponsor: Bristol-Myers Squibb, Sidney Kimmel Comprehensive Cancer Center, Syndax Pharmaceuticals
Therapies Used in This Trial: Nivolumab, Entinostat